Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 701

1.

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome.

Rozovski U, Hazan-Halevy I, Calin G, Harris D, Li P, Liu Z, Keating MJ, Estrov Z.

J Vis Exp. 2016 Jun 15;(112). doi: 10.3791/53300.

PMID:
27341356
2.

Reactivation of smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of smac mimetic.

Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V.

Oncotarget. 2016 Mar 29. doi: 10.18632/oncotarget.8462. [Epub ahead of print]

3.

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ.

Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.

4.

Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.

Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V.

Leukemia. 2016 May 20. doi: 10.1038/leu.2016.129. [Epub ahead of print] No abstract available.

PMID:
27198052
5.

Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.

Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM.

Cancer. 2016 May 16. doi: 10.1002/cncr.30069. [Epub ahead of print]

PMID:
27182988
6.

Ibrutinib for Chronic Lymphocytic Leukemia.

Sharman JP, Mato AR, Keating MJ.

N Engl J Med. 2016 Apr 21;374(16):1592-3. doi: 10.1056/NEJMc1600328#SA1. No abstract available.

PMID:
27096595
7.

At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells.

Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z.

J Immunol. 2016 May 15;196(10):4400-9. doi: 10.4049/jimmunol.1402108. Epub 2016 Apr 13.

PMID:
27076684
8.

Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.

Liu PP, Liu J, Jiang WQ, Carew JS, Ogasawara MA, Pelicano H, Croce CM, Estrov Z, Xu RH, Keating MJ, Huang P.

Oncogene. 2016 Apr 11. doi: 10.1038/onc.2016.103. [Epub ahead of print]

PMID:
27065330
9.

Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses.

Lamothe B, Wierda W, Keating MJ, Gandhi V.

Clin Cancer Res. 2016 Mar 29. pii: clincanres.2522.2015. [Epub ahead of print]

PMID:
27026200
10.

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA.

Haematologica. 2016 Jun;101(6):e254-8. doi: 10.3324/haematol.2015.138289. Epub 2016 Mar 24. No abstract available.

11.

Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.

Falchi L, Vitale C, Keating MJ, Lerner S, Wang X, Elhor Gbito KY, Strom S, Wierda WG, Ferrajoli A.

Ann Oncol. 2016 Jun;27(6):1100-6. doi: 10.1093/annonc/mdw072. Epub 2016 Feb 23.

PMID:
26912560
12.

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A.

Clin Cancer Res. 2016 May 15;22(10):2359-67. doi: 10.1158/1078-0432.CCR-15-2476. Epub 2016 Jan 5.

PMID:
26733610
13.

Metabolism pathways in chronic lymphocytic leukemia.

Rozovski U, Hazan-Halevy I, Barzilai M, Keating MJ, Estrov Z.

Leuk Lymphoma. 2016 Apr;57(4):758-65. doi: 10.3109/10428194.2015.1106533. Epub 2015 Dec 8.

PMID:
26643954
14.

β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.

Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG.

Cancer. 2016 Feb 15;122(4):565-73. doi: 10.1002/cncr.29794. Epub 2015 Nov 20.

PMID:
26588193
15.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.

Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ.

Blood. 2016 Jan 21;127(3):303-9. doi: 10.1182/blood-2015-09-667675. Epub 2015 Oct 22.

16.

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

Patel V, Keating MJ, Wierda WG, Gandhi V.

Leuk Lymphoma. 2016 Jun;57(6):1494-7. doi: 10.3109/10428194.2015.1102243. Epub 2015 Nov 16. No abstract available.

PMID:
26440741
17.

Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.

Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z.

Leuk Lymphoma. 2016 May;57(5):1054-9. doi: 10.3109/10428194.2015.1092527. Epub 2015 Oct 19.

PMID:
26402369
18.

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.

Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA.

Br J Haematol. 2015 Dec;171(5):726-35. doi: 10.1111/bjh.13659. Epub 2015 Sep 11.

PMID:
26358140
19.

Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome.

Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG.

Leukemia. 2016 Feb;30(2):325-30. doi: 10.1038/leu.2015.227. Epub 2015 Aug 20.

20.

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM.

Cancer. 2015 Nov 1;121(21):3869-76. doi: 10.1002/cncr.29605. Epub 2015 Jul 28.

PMID:
26218678
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk